NCT05111366View on ClinicalTrials.gov

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

PHASE2UnknownINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

January 20, 2024

Study Completion Date

May 20, 2024

Conditions
Hepatocellular CarcinomaAdjuvant Therapy
Interventions
DRUG

TQB2450 injection

TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.

DRUG

Anlotinib hydrochloride capsules

Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.

Trial Locations (1)

410005

RECRUITING

Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Xianhai Mao

OTHER